Welsh School of Pharmacy

Chan K.C., Knox W.F., Gee J.M.W., Morris J., Nicholson R.I., Potten C.S. and Bundred N.J. (2002) Effects of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition on Epithelial Proliferation in Normal and Premalignant Breast. Cancer Res 62, 122-128.

Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J. (2002) Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition. J Clin Oncol 20, 110-24.

Miremadi, A., Pinder, S. E., Lee, A. H., Bell, J. A., Paish, E. C., Wencyk, P., Elston, C. W., Nicholson, R. I., Blamey, R. W., Robertson, J. F., and Ellis, I. O.( 2002) Neuroendocrine differentiation and prognosis in breast adenocarcinoma, Histopathology. 40: 215-22.

Nicholson, R. I., Miller, W., and Lonning, P. E. (2002) For which tumour types should endocrine therapy be restricted? Eur J Cancer. 38: 617-619.

Nicholson, R.I., Hutcheson, I.R., Harper, M.E., Knowlden, J.M., Barrow, D., McClelland, R.A., Jones, H.E., Wakeling, A.E. & Gee, J.M. (2002). Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Ann N Y Acad Sci, 963, 104-15.

Harper, M. E., Goddard, L., Glynne-Jones, E., Assender, J., Dutkowski, C. M., Barrow, D., Dewhurst, O. L., Wakeling, A. E., and Nicholson, R. I. (2002) Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor, Prostate. 52: 59-68.

Bundred, N.J., Anderson, E., Nicholson, R.I., Dowsett, M., Dixon, M. & Robertson, J.F. (2002). Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen. Anticancer Res, 22: 2317-9.

Knowlden, J.M., Hutcheson, I.R., Jones, H.E., Madden, T.A., Gee, J.M.W., Harper, M.E., Barrow, D., Wakeling, A.E. & Nicholson, R.I. (2003). Elevated Levels of EGFR/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells. Endocrinology, 144, 1032-44.

Taylor, K.M. & Nicholson, R.I. (2003). The LZT proteins; the LIV-1 subfamily of zinc transporters. Biochim Biophys Acta, 1611, 16-30.

Nicholson, R.I., Gee, J.M., Knowlden, J., McClelland, R., Madden, T.A., Barrow, D. & Hutcheson, I. (2003). The biology of antihormone failure in breast cancer. Breast Cancer Res Treat, 80 Suppl 1, S29-34; discussion S35.

Gee, J.M. & Nicholson, R.I. (2003). Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization. Breast Cancer Res, 5, 126-9.

Taylor, K.M., Morgan, H.E., Johnson, A., Hadley, L.J. & Nicholson, R.I. (2003). Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters. Biochem J, 375, 51-9.

Gee, J.M., Harper, M.E., Hutcheson, I.R., Madden, T.A., Barrow, D., Knowlden, J.M., McClelland, R.A., Jordan, N., Wakeling, A.E. & Nicholson, R.I. (2003). The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology, 144, 5105-17.

Hutcheson, I.R., Knowlden, J.M., Madden, T.A., Barrow, D., Gee, J.M., Wakeling, A.E. & Nicholson, R.I. (2003). Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat, 81, 81-93.

Nicholson, R.I., Wakeling, A.E. & Gee, J.M.W. (2003). Prospects for combining hormonal and anti-EGFR inhibition. Breast Cancer Online, 6.

Nicholson, R.I., Hutcheson, I.R., Knowlden, J.M., Jones, H.E., Harper, M.E., Jordan, N., Hiscox, S.E., Barrow, D. & Gee, J.M. (2004). Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res, 10, 346S-54S.

Taylor, K.M., Morgan, H.E., Johnson, A. & Nicholson, R.I. (2004). Structure-function analysis of HKE4, a member of the new LIV-1 subfamily of zinc transporters. Biochem J, 377, 131-9.

Come, S.E., Buzdar, A.U., Arteaga, C.L., Bissell, M.J., Brown, M.A., Ellis, M.J., Goss, P.E., Green, J.E., Ingle, J.N., Lee, A.V., Medina, D., Nicholson, R.I., Santen, R.J., Schiff, R. & Hart, C.S. (2004). Proceedings of the third international conference on recent advances and future directions in endocrine manipulation of breast cancer: conference summary statement. Clin Cancer Res, 10, 327S-30S.

Harper, M.E., Goddard, L., Smith, C. & Nicholson, R.I. (2004). Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines. Prostate, 58, 13-22.

Jones, H.E., Nicholson, R.I., Hutcheson, I.R., Knowlden, J.M., Harper, M.E., Jordan, N., Hiscox, S.E., Barrow, D. & Gee, J.M.W. (2004). Endocrine resistance in breast cancer:therapeutic intervention using signal transduction inhibitors. Advances in Breast cancer, 1, 3-9.

Rushmere, N.K., Knowlden, J.M., Gee, J.M., Harper, M.E., Robertson, J.F., Morgan, B.P. & Nicholson, R.I. (2004). Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. Int J Cancer, 108, 930-6.

Osborne, C.K., Wakeling, A. & Nicholson, R.I. (2004). Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer, 90 Suppl 1, S2-6.

Rampaul, R.S., Pinder, S.E., Wencyk, P.M., Nicholson, R.I., Blamey, R.W., Robertson, J.F. & Ellis, I.O. (2004). Epidermal growth factor receptor status in operable invasive breast cancer: is it of any prognostic value? Clin Cancer Res, 10, 2578.

Abd El-Rehim, D.M., Pinder, S.E., Paish, C.E., Bell, J., Blamey, R., Robertson, J.F., Nicholson, R.I. & Ellis, I.O. (2004). Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol, 203, 661-671.

Gee, J.M., Giles, M.G. & Nicholson, R.I. (2004). Extreme growth factor signalling can promote oestrogen receptor-alpha loss: therapeutic implications in breast cancer. Breast Cancer Res, 6, 162-163.

Hiscox, S., Morgan, L., Barrow, D., Dutkowski, C., Wakeling, A. & Nicholson, R.I. (2004). Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clin Exp Metastasis, 21, 201-12.

Jordan, N.J., Gee, J.M., Barrow, D., Wakeling, A.E. & Nicholson, R.I. (2004). Increased Constitutive Activity of PKB/Akt in Tamoxifen Resistant Breast Cancer MCF-7 Cells. Breast Cancer Res Treat, 87, 167-80.

Taylor, K.M., Nicholson, R.I. & Hiscox, S.E. (2004). Zinc transporter LIV-1; A link between cellular development and cancer progression. Trends Endocrinology and Metabolism, 15, 461-63.

Nicholson, R.I., Giles, M.G., Hutcheson, I.R., Madden, T.A., and Gee, J.M.W. (2004) Impact of altered growth factor signalling on endocrine response in breast cancer and the transition from ER+ to ER- disease.  Breast Cancer Online.

Rampaul, R.S., Pinder, S.E., Nicholson, R.I., Gullick, W.J., Robertson, J.F.R. & Ellis, I.O. (2004). Clinical Value of Epidermal Growth Factor Receptor Expression in Primary Breast Cancer. Breast Cancer Online.

Nicholson, R.I., Jones, H.E. & Gee, J.M.W. (2004). EGFR Inhibitors in Breast Cancer. Signal, 5, 9-13.   

Nicholson, R.I., Staka, C., Boyns, F., Hutcheson, I.R. & Gee, J.M. (2004). Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocr Relat Cancer, 11, 623-41.

Taylor, K.M., Morgan, H.E., Johnson, A. & Nicholson, R.I. (2005). Structure-function analysis of a novel member of the LIV-1 subfamily of zinc transporters, ZIP14. FEBS Lett, 579, 427-32.

Nicholson, R.I., Hutcheson, I.R., Britton, D., Knowlden, J.M., Jones, H.E., Harper, M.E., Hiscox, S.E., Barrow, D. & Gee, J.M. (2005). Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. J Steroid Biochem Mol Biol, 93, 257-62.

Vicent, M.J., Greco, F., Nicholson, R.I., Paul, A., Griffiths, P.C. & Duncan, R. (2005). Polymer Therapeutics Designed for a Combination Therapy of Hormone-Dependent Cancer. Angew Chem Int Ed Engl, 44, 4061-4066.

Knowlden, J.M., Hutcheson, I.R., Barrow, D., Gee, J.M. & Nicholson, R.I. (2005). IGF-IR signalling in tamoxifen-resistant breast cancer: A supporting role to the EGFR. Endocrinology.

Hiscox, S., Jiang, W.G., Obermeier, K., Taylor, K., Morgan, L., Burmi, R., Barrow, D. & Nicholson, R.I. (2005). Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer.

Staka, C.M., Nicholson, R.I. & Gee, J.M. (2005). Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model. Endocr Relat Cancer, 12 Suppl 1, S85-97.

Nicholson, R.I., Hutcheson, I.R., Hiscox, S.E., Knowlden, J.M., Giles, M., Barrow, D. & Gee, J.M. (2005). Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr Relat Cancer, 12 Suppl 1, S29-36.

Jones, H.E., Gee, J.M., Taylor, K.M., Barrow, D., Williams, H.D., Rubini, M. & Nicholson, R.I. (2005). Development of strategies for the use of anti-growth factor treatments. Endocr Relat Cancer, 12 Suppl 1, S173-82.

Gee, J.M., Howell, A., Gullick, W.J., Benz, C.C., Sutherland, R.L., Santen, R.J., Martin, L.A., Ciardiello, F., Miller, W.R., Dowsett, M., Barrett-Lee, P., Robertson, J.F., Johnston, S.R., Jones, H.E., Wakeling, A.E., Duncan, R. & Nicholson, R.I. (2005). Consensus statement. Endocr Relat Cancer, 12 Suppl 1, S1-7.

Gee, J.M., Robertson, J.F., Gutteridge, E., Ellis, I.O., Pinder, S.E., Rubini, M. & Nicholson, R.I. (2005). Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer, 12 Suppl 1, S99-S111.

Duncan, R., Vicent, M.J., Greco, F. & Nicholson, R.I. (2005). Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr Relat Cancer, 12 Suppl 1, S189-99.

Agrawal, A., Gutteridge, E., Gee, J.M., Nicholson, R.I. & Robertson, J.F. (2005). Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer, 12 Suppl 1, S135-44.

Britton, D.J., Hutcheson, I.R., Knowlden, J.M., Barrow, D., Giles, M., McClelland, R.A., Gee, J.M. & Nicholson, R.I. (2005). Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat, 1-16.

Dowsett, M., Nicholson, R.I. & Pietras, R.J. (2005). Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res Treat, 93 Suppl 4, 11-8.

Greco, F., Vicent, M.J., N.A., P., Nicholson, R.I. & Duncan, R. (2005). HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines. J Drug Targetting.

Nicholson, R.I. & Johnston, S.R. (2005). Endocrine therapy - current benefits and limitations. Breast Cancer Res Treat, 93 Suppl 4, 3-10.

Rampaul, R.S., Pinder, S.E., Nicholson, R.I., Gullick, W.J., Robertson, J.F. & Ellis, I.O. (2005). Clinical value of epidermal growth factor receptor expression in primary breast cancer. Adv Anat Pathol, 12, 271-3.

De Martino, G., Edler, M.C., La Regina, G., Coluccia, A., Barbera, M.C., Barrow, D., Nicholson, R.I., Chiosis, G., Brancale, A., Hamel, E., Artico, M. & Silvestri, R. (2006). New Arylthioindoles: Potent Inhibitors of Tubulin Polymerization. 2. Structure-Activity Relationships and Molecular Modeling Studies. J Med Chem, 49, 947-954.

Hiscox, S., Jiang, W.G., Obermeier, K., Taylor, K., Morgan, L., Burmi, R., Barrow, D. & Nicholson, R.I. (2006). Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer, 118, 290-301.

Sarwar, N., Kim, J.-S., Jiang, J., Peston, D., Sinnett, H.D., Madden, P., Gee, J.M., Nicholson, R.I., Lykkesfeldt, A.E., Shousha, S., Coombes, R.C. & Ali, S. (2006). Phosphorylation of ERá at serine 118 in primary breast cancer and in tamoxifen resistant tumors is indicative of a complex role for ERá phosphorylation in breast cancer progression. Endocr Relat Cancer. 13(3):851-861.

Cui, Y., Parra, I., Zhang, M., Hilsenbeck, S.G., Tsimelzon, A., Furukawa, T., Horii, A., Zhang, Z.Y., Nicholson, R.I. & Fuqua, S.A. (2006). Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res, 66, 5950-9.

Taylor, K. & Nicholson, R. (2006). Fear of intimacy - a close LIV-1 acquaintancy? Development, 133, 3053.

Sakamaki, T., Casimiro, M.C., Ju, X., Quong, A.A., Katiyar, S., Liu, M., Jiao, X., Li, A., Zhang, X., Lu, Y., Wang, C., Byers, S., Nicholson, R., Link, T., Shemluck, M., Yang, J., Fricke, S.T., Novikoff, P.M., Papanikolaou, A., Arnold, A., Albanese, C. & Pestell, R. (2006). Cyclin D1 determines mitochondrial function in vivo. Mol Cell Biol, 26, 5449-69.

Greco, F., Vicent, M.J., Gee, S., Jones, A.T., Gee, J., Nicholson, R.I. & Duncan, R. (2006). Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells. J Control Release, 117, 28-39.

Hiscox, S., Jordan, N.J., Jiang, W., Harper, M., McClelland, R., Smith, C. & Nicholson, R.I. (2006). Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions. Endocr Relat Cancer, 13, 1085-99.

Hiscox S, Morgan L, Green T, Nicholson RI. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S53-9.

Hutcheson IR, Knowlden JM, Jones HE, Burmi RS, McClelland RA, Barrow D, Gee JM, Nicholson RI. Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S89-97. 

Gee JM, Shaw VE, Hiscox SE, McClelland RA, Rushmere NK, Nicholson RI.

Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S77-88. 

Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat. 2006 Jun;97(3):263-74. 

Robertson, J.F., Semiglazov, V., Nemsadze, G., Dzagnidze, G., Janjalia, M., Nicholson, R.I., Gee, J.M. & Armstrong, J. (2007). Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancer. Eur J Cancer, 43, 64-70.

Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol. 2007 Oct 20;25(30):4772-8.

Taylor KM, Morgan HE, Smart K, Zahari NM, Pumford S, Ellis IO, Robertson JF, Nicholson RI.  The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer. Mol Med. 2007 Jul-Aug;13(7-8):396-406. 

Nicholson RI, Hutcheson IR, Jones HE, Hiscox SE, Giles M, Taylor KM, Gee JM.

Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.

Rev Endocr Metab Disord. 2007 Sep;8(3):241-53.

Hiscox S, Jordan NJ, Morgan L, Green TP, Nicholson RI. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clin Exp Metastasis. 2007;24(3):157-67.

Jones HE, Gee JM, Hutcheson IR, Knowlden JM, Barrow D, Nicholson RI.

Growth factor receptor interplay and resistance in cancer. Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S45-51. 

Jones HE, Gee JM, Barrow D, Tonge D, Holloway B, Nicholson RI. Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells. Br J Cancer. 2006 Jul 17;95(2):172-80.

Assender JW, Gee JM, Lewis I, Ellis IO, Robertson JF, Nicholson RI. Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. J Clin Pathol. 2007 Nov;60(11):1216-21.

Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, Robertson JF, Blamey R, Gee J, Nicholson RI, Lee AH, Ellis IO. Invasive lobular carcinoma of the breast: Response to hormonal therapy and outcomes. Eur J Cancer. 2007 Nov 20; [Epub ahead of print]

Knowlden JM, Jones HE, Barrow D, Gee JM, Nicholson RI, Hutcheson IR.

Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Res Treat. 2007 Sep 28; [Epub ahead of print]

 

Books

Endocrine Therapy in Breast Cancer (2002), J F R Robertson, R I Nicholson and D F Hayes (Editors). Martin Dunitz Ltd: Londo

 

Gee, J.M.W., Madden, T.A., Robertson, J.F.R. & Nicholson, R.I. (2002). Clinical response and resistance to SERMS. In Endocrine Therapy in Breast Cancer, Robertson, J.F.R., Nicholson, R.I. & Hayes, D.F. (eds) pp. 155-190. Martin Dunitz Ltd: London.

Gee JMW and Nicholson RI (2002). The Breast cancer Phenotype and endocrine response: Implications for new drug development initiatives. In Breast Cancer Prognosis, Treatment and Prevention, Pasqualini JR (ed) pp301-342. Marcel Dekker Inc: New York.

Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow, D, McClellend RA, Jones HE, Wakeling AE and Gee JMW (2002). Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor positive breast cancer. In Novel Approaches to Prevention and Treatment, vol 963, pp 104-116.  Castagnetta L et al (eds). Annals of New York Academy of Sciences

Nicholson, R.I. & Gee, J.M.W. (2002). Future Prospects for the Endocrine Management of Breast Cancer. In Endocrine Therapy of Breast Cancer, Robertson, J.F.R., Nicholson, R.I. & Hayes, D.F. (eds) pp. 265-274. Martin Dunitz Ltd: London. Humana Press Inc: Totowa, NJ.

Nicholson, R.I., Madden, T.A., Bryant, S. & Gee, J.M.W. (2002). Cellular and Molecular Actions of Oestrogens and Antioestrogens in Breast Cancer. In Endocrine Therapy of Breast Cancer, Robertson, J.F.R., Nicholson, R.I. & Hayes, D.F. (eds) pp. 127-154. Martin Dunitz Ltd: London.

Willsher, P.C., Kenny, F.S., Gee, J.M.W., Nicholson, R.I. & Robertson, J.F.R. (2002). Biological changes in primary breast cancer during antioestrogen therapies. In Endocrine Therapy in Breast Cancer, Robertson, J.F.R., Nicholson, R.I. & Hayes, D.F. (eds) pp. 209-232. Martin Dunitz Ltd: London.

Gee, J.M.W. & Nicholson, R.I. (2002). The Breast Cancer Phenotype and Endocrine Response: Implications for New Drug Development Initiatives. In Breast Cancer: Prognosis, Treatment and Prevention, Pasqualini, J.R. (ed) pp. 301-342. Marcel Dekker Inc: New York.

Hutcheson, I.R., Gee, J.M.W. & Nicholson, R.I. (2003). MAP Kinase family members and endocrine response and survival in breast cancer. In Commentaries in breast cancer: Prognostic and predictive factor, Walker, R.A. (ed) pp. 147-167. Martin Dunitz Ltd: London.

Jasani, B., Douglas-Jones, A., Rhodes, A., Wozniak, S., Barrett-Lee, P., Gee, J.M.W. & Nicholson, R.I. (2005). Measurement of Estrogen Receptor Status by Immunocytochemistry in Paraffin Wax Sections. In Methods in Molecular Medicine, Vol. 120: Breast Cancer Research Protocols., Brooks, S.A. & Harris, A.L. (eds) pp. 127-146.

Hiscox S, Borley A, Nicholso RI and Barrett-Lee P. (2006). Epithelial-Mesenchymal Transition (EMT) and its involvement in endocrine resistance in breast cancer. In: Cancer Drug Resistance Research Perspectives, Nova Science Publishers, Inc. Ed: Liman S Torres. pp81-95

Hiscox S, Gee JM and Nicholson, RI. (2006). Endocrine resistance and breast cancer invasion, In: Metastasis of Breast Cancer,. Kluwer Publishers. Ed: W Jiang, O Foysted and RE Mansel. pp74-83

Nicholson RI, Hutcheson IR, Jones HE, Taylor KM, Hiscox SE and Gee, JMW (2008, In Press). Compensatory signalling induced by anti-hormone and anti-growth factor therapies in breast cancer: a starting point for the development of resistance to targeted therapies. In Breast Cancer: Prognosis, treatment and prevention,  Pasqualini JR (ed). Taylor and Francis.

 

AstraZeneca EGFR Advisory Board.  Miami, Florida.  Feb 9^th – 11^th 2002.

3^rd European Breast Cancer Conference.  Barcelona, Spain.  March 19^th – 23^rd 2002.  Targeting of Oestrogen and Growth Factor Signalling Pathways in the Therapy of Breast Cancer:  Implications for chemoprevention.

AstraZeneca International Iressa Breast Cancer Advisory Board.  Chicago, USA.  April 16^th – 17^th 2002.

AstraZeneca Oncology Workshop.  Cambridge, UK.  25^th July 2002.

AstraZeneca Weekend Oncology Workshop.  Melbourne, Australia.  Sept 6^th – 8^th 2002.

Arimidex Stand Alone Meeting.  Cannes, France.  Sept 27^th – 29^th 2002.

Aromatase 2002.  Kyoto, Japan.  Oct 26^th – 30^th 2002.  Growth factor receptor antagonists and endocrine resistance.

AstraZeneca Iressa Translational Advisory Board.  Frankfurt, Germany.  Nov 17^th – 19^th 2002.

Growth Signalling in Cancer.  Palermo, Sicily.  Nov 28^th – Dec 1^st 2002. Cross-talk between Estrogen and Growth Factor Signalling: Therapeutic Implications.

AstraZeneca Sponsored Symposium. San Antonio, USA.  Dec 10^th 2002.  Role of EGFR Signalling in Endocrine Resistance in Breast Cancer.

25^th Annual San Antonio Breast Cancer Symposium.  San Antonio, USA.  Dec 11^th – 14^th 2002.  Growth Factor Pathways and Endocrine Resistance.

AstraZeneca Faslodex Advisory Board. San Antonio, USA.  Dec 12^th 2002.

National Breast Pathology Course, Nottingham 8-9^th April, 2003. Beyond ER as a monitor of endocrine response in breast cancer.

NCI International Meeting on Angiogenesis in cancer.   Reykjavik, Iceland 26^th – 28^th June 2003.

Australian New Zealand Breast cancer Trials Group 25^th Annual Participants Scientifci Meeting.  Adelaide, Australia 8^th – 12^th July 2003.  EGFR, ER and Endocrine therapy: Strategies to avoid resistance.

2^nd Gleneagles Conference on Endocrine Therapy for Breast Cancer.  The Gleneagles Hotel, Perthshire, Scotland.  6^th – 9^th July 2003. Growth factor signalling in endocrine resistance: Dual targeting, a new approach.

3^rd International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer.  Cambridge Massachusetts, USA.  July 21^st – 22^nd 2003. Interactions between erbB and IGF-1R signalling pathways in the regulation of endocrine resistant growth: New therapeutic opportunities.

8^th Nottingham International Breast Cancer Meeting.  Nottingham, UK 16^th – 19^th September 2003.  Endocrine, biology and clinical session - Chairman

2^nd International Symposium on Signal Transduction Modulators in Cancer Therapy.  Amsterdam, The Netherlands 23^rd – 25^th October 2003. Acquired resistance to gefitinib ('Iressa', ZD1839) in breast cancer cells results from increased IGF1-R signalling and generates cross-resistance to trastuzumab.

26^th Annual San Antonio Breast Cancer Symposium. San Antonio, USA 3 – 6 Dec 2003.

95^th Annual AACR Meeting.  Orlando, Florida 27^th – 31^st March 2004.

International ERPM 2004.  Montpellier, France 31^st Mar – 2^nd April 2004. Growth factor signalling networks and resistance to endocrine agents: new therapeutic strategies.

 

Asia Pacific Oncology Summit.  Shanghai 14-15 May 2004.  Growth Factor Signalling Networks and Response to Endocrine Agents:  A New Way Forward for the Effective Therapy of Breast Cancer.

16^th International symposium of the Journal of Steroid Biochemistry and Molecular Biology.  Seefeld, Austria 5-8 June. The targeting of growth factor signal transduction cascades improves the antitumour activity of antihormonal drugs in experimental breast cancer.

Aromatase 2004.  Edinburgh, Scotland 6^th – 8^th Sept 2004.

ONCOPOOL funding meeting.   Glasgow, Scotland 23^rd – 24^th Sept 2004.

16^th EORTC-NCI-AACR Symposium.  Geneva, Switzerland 28^th Sept – 1^st Oct 2004.

AstraZeneca Global Breast cancer Summit Meeting “Finding Answers Together”. Montreux, Switzerland 14-16 October 2004.

27^th Annual San Antonio Breast Cancer Symposium. San Antonio, USA 8^th – 11^th Dec 2004.

AstraZeneca Advisory Group Meeting:  ‘Faslodex’ as Adjuvant Therapy for Early Breast Cancer. New York City, USA  19^th - 20^th January 2005.

Tenovus/Astrazeneca Workshop: “Therapeutic resistance in breast cancer: Impact of growth factor signalling pathways and implications for future treatment". SERMs and pure anti-oestrogens.   Cardiff, UK 3^rd – 4^th Feb 2005. (Conference Organiser).

AACR: Advances in Breast Cancer Research.  California, USA 21^st -25^th September 2005. 

5^th FGOG International Meeting: Endocrine Treatment Prevention of Breast and Gynaecological Cancers.  Targeting the EGFR network: Trstuzumab and gefitinib .  Brussels, Belgium 26^th – 28^th January 2006.

AstraZeneca Japanese trial meeting.  Antihormones in Cancer - Keynote Lecture.  Tokyo, Japan 25th-26^th February 2006. 

Tenovus/AstraZeneca International Workshop - Growth factor signalling pathways in cancer progression: complexities and therapeutic opportunities. Cardiff, UK.   20^th - 21^st April 2006 (Conference organiser).

17^th International Symposium of the Journal of Steroid Biochemistry & Molecular Biology. Steroid receptors, mechanism of action, co-activators and co-pressors.   Seefeld, Austria 31^st May – 3^rd June 2006.  (Chair of session).

5^th Annual International Congress on the Future of Breast cancer.  Growth Factor Networks in Breast cancer Growth and Survival. Kohala Coast, Hawaii 3^rd – 6^th August 2006.

Edinburgh 2006: Controversies in Breast Cancer.  Growth and development of breast cancer.  Edinburgh, Scotland 4^th – 5^th September 2006.

AstraZeneca ‘Think Tank’ meeting.  New York, USA 23^rd – 24^th February 2007.

AC Borley, PJ Barrett-Lee, JMW Gee, V Smith, RI Nicholson and SE Hiscox. Anti-estrogens promote an invasive phenotype in intercellular adhesion deficient breast cancer cells. 30th San Antonio Breast Cancer Symposium, December 2007

Hutcheson IR, Barrow D, Hasmann M, Nicholson RI (2007). Induction of erbB3/heterodimers mediates resistance to pertuzumab in a tamoxifen-resistant MCF-7 breast cancer cell line. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics Proceedings A118, p102.

Hill N, Gee JMW, Quirk P, Sharma-Oates A, Nicholson RI, Thomas G, Leonard R, Wagstaff J and Lewis P (2007).  Superstes: cancer survival query tool. Eur J Cancer 2003, Suppl 1.

Taylor KM, Smart K, Hiscox S, Zahari NM, Gee JM, McClelland RA, Ackland L and Nicholson RI. (2006) The LIV-1 subfamily as new targets in anti-hormone resistance and metastasis of breast cancer, Zinc Signals, Siena, Italy

Jones HE, Gee JMW, Barrow D, Holloway B, Tonge D & Nicholson RI. Maintenance of EGFR phosphorylation by the IGF-1R in the presence of gefitinib in lung cancer cells: co-targeting the EGFR and IGF-1R maximises anti-tumour effects. Proceedings of the 4th International Symposium on Signal Transduction Modulators in Cancer Therapy Abs. P210. Amsterdam, Netherlands, 2006.

Hiscox S, Borley A, Barratt-Lee P, Jordan NJ, Gee J, Shaw V, McClelland R, Nicholson RI. Tamoxifen promotes cellular invasion in intercellular-adhesion deficient breast cancer cells. 14th International conference of the Journal of Steroid Biochemistry and Molecular Biology, June 2006

Burmi, R.S., McClelland, R.A., Barrow, D., Ellis, I.O., Robertson, J.F.R., Nicholson, R.I. & Gee, J.M.W. (2006). Microarray studies reveal novel genes associated with endocrine resistance in breast cancer Breast Cancer Res, 8, S11.

Hiscox S, Green TP and Nicholson RI. Combination therapy using AZD0530 and tamoxifen prevents anti-hormone resistance in breast cancer cells. 29th San Antonio Breast Cancer Symposium, December 2006

Hutcheson IR, Thomas NP, Barrow D, Harper M, Campbell L, Gumbleton M & Nicholson RI. (2005). Caveolin-1 expression in tamoxifen-sensitive and -resistant MCF-7 breast cancer cells. Eur J Cancer  suppl. 3, 24

Taylor KM, Vichova P, Hiscox S, and Nicholson RI. (2005) Zinc-dependant activation of EGFR and co-localisation with vinculin in focal adhesions in Tamoxifen resistant breast cancer cells. Beatson Cancer Conference, Glasgow.

Hiscox S, Harper M, Jiang WG, McCelland R, Smith C, Nicholson R. Elevated c-met expression accompanies endocrine resistance in MCF7 breast cancer cells and promotes in vitro cell migration and invasion. 28th San Antonio Breast Cancer Symposium, December, 2005.

Hiscox S, Barrow D, Green T, Nicholson R. Adhesion independent focal adhesion kinase activation invcolves Src and promotes cell adhesion and motility in tamoxifen-resistant MCF-7 cells and is inhibited by the Src/Abl kinase inhibitor, AZD0530. 96th AACR Meeting, Anaheim, California, 16th-20th April, 2005

Shaw, V.E., Gee, J.M.W., McClelland, R.A., Morgan, H., Rushmere, N. & Nicholson, R.I. (2005). Identification of anti-hormone induced genes as potential therapeutic targets in breast cancer. Proc Amer Assoc Cancer Res, 46, Abstract 3706.

Staka, C.M., Gee, J.M.W. & Nicholson, R.I. (2005). Potential of growth factor signalling kinases/ERalpha crosstalk to undermine the effects of estrogen deprivation in vitro. Proc Amer Assoc Cancer Res, 46, Abstract 3668.

Knowlden JM, Hutcheson IR, Gee JM, Barrow D, Wakeling AE  & Nicholson RI (2004). Gefitinib (IRESSA) promotes IGF-1R signalling in tamoxifen-resistant MCF-7 breast cancer cells: role of IRS-1. Breast Cancer Res. Treat 88: P1111.

Hutcheson IR, Knowlden JM, Jones HE, Hiscox SE, Gee JM & Nicholson RI (2004). Oestrogen and growth factor cross-talk in endocrine-resistant breast cancer cells: Therapeutic implications. Intl J Mol Med 14: S81

Hutcheson IR, Knowlden JM, Barrow D & Nicholson RI (2004). IGF-IR/EGFR crosstalk in tamoxifen resistant MCF-7 breast cancer cells. AACR Proceedings 45: 5189.

Gee JMW, Gutteridge E, Robertson JF, Wakeling AE, Jones HE, Nicholson RI. Biological markers during early treatment of tamoxifen-resistant breast cancer with gefitinib (‘Iressa’). Breast Cancer Res. Treat. 88 (suppl 1) S32, Abs 30. 27th Annual San Antonio Breast Cancer Symposium, 8– 11 Dec 2004 – San Antonio, USA, 2004.

Hutcheson IR, Gee JMW, Barrow D, Jones HE, Wakeling AE, Nicholson RI. Treatment of tamoxifen-resistant MCF-7 breast cancer cells with either gefitinib (‘Iressa’) or trastuzumab (Herceptin®) generates cross-resistant phenotypes. Breast Cancer Res. Treat. 88 (suppl 1) S145, Abs 3097 . 27th Annual San Antonio Breast Cancer Symposium, 8– 11 Dec, San Antonio, USA, 2004. Jones HE, Gee JMW, Barrow D, Wakeling AE, Guy S, Nicholson RI. De novo resistance to EGFR blockade by gefitinib (‘Iressa’, ZD1839) in colo-rectal cancer cells involves increased Insulin Receptor Isoform A signalling. Eur. J.Cancer 2 102, Abs 336: 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, September, Geneva, Switzerland, 2004. Gee, J., Shaw, V., Burmi, R., McClelland, R., Morgan, H., Harper, M., Hiscox, S., Barrow, D., Lewis, P. & Nicholson, R. (2004). Array profiling of survival and resistance genes in anti-hormone-treated breast cancer cells. Intl J Mol Med, 14, S81. Gee, J.M.W., Gutteridge, E., Robertson, J.F., Wakeling, A.E., Jones, H.E.  & Nicholson, R.I. (2004). Biological markers during early treatment of tamoxifen-resistant breast cancer with gefitinib (‘Iressa’). Breast Cancer Res Treat, 88, S216. Jones HE, Gee JMW, Taylor KM, Barrow D, Guy S, Wakeling AE, Nicholson RI. Acquired resistance to gefitinib (Iressa, ZD1839) in breast cancer cells results from increased IGF1-R signalling and generates cross-resistance to trastuzumab. Proceedings of the 2nd International Symposium on Signal Transduction Modulators in Cancer Therapy, Abs. O22.  October, Amsterdam, Netherlands, 2003.     Jones HE, Goddard L, Gee JMW, Hiscox S, Harper ME, Rubini M, Barrow D, Guy S, Wakeling AE, Nicholson RI. Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; IRESSATM) in DU145 human prostate cancer cells. Proceedings of the 5th World Congress on Urological Research, London UK, September, 2003. Hutcheson IR, Knowlden JM, Barrow D, Jones HE, Nicholson RI. The novel ER down-regulator, Faslodex, modulates EGFR/MAPK activity in tamoxifen-resistant MCF-7 breast cancer cells.  Clin. Cancer Res.  7: 622. AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics, 29 Oct – 2 Nov Miami, Florida, USA, 2001.